{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:40:11Z","timestamp":1792806011876,"version":"4.5.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n            <jats:title>Background and Aims:<\/jats:title>\n            <jats:p>Immunotherapy-based regimes have changed the management of HCC. However, evidence of efficacy in patients with impaired liver function is unknown. This systematic review and meta-analysis assesses survival of HCC patients and liver dysfunction treated with immunotherapy-based regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Systematic review and meta-analysis of original articles or abstracts reporting survival of HCC patients treated with immunotherapy according to liver function between 2017 and 2022. Overal survival (OS) according to restricted mean survival time (RMST) and median OS, and hazard ratio (HR) of Child-Pugh B or B\/C versus Child-Pugh A were assessed while considering the line of treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of the 2218 articles considered, 15 articles recruiting 2311 patients were included. Of these, 639 (27.7%) were Child-Pugh B and 34 (1.5%) C. RMST was 8.36 (95% CI, 6.15\u201310.57; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>=93%) months, estimated from 8 studies. The HR was reported in 8 studies for survival between Child-Pugh B versus Child-Pugh A and metanalysis disclosed a 1.65 HR (95% CI,1.45\u20131.84; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>=0% heterogeneity; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.45). Treatment line data were available for 47% of the patients and 3 studies included patients treated with atezolizumab-bevacizumab in the first line.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The high heterogeneity across studies reflects the incapacity of the current evidence to support the indication of immunotherapy in HCC patients with relevant liver dysfunction. It is mandatory to report complementary information to Child-Pugh classification such as prior liver decompensation, use of concomitant medication to control ascites, or signs of clinically significant portal hypertension to allow better patient stratification in future studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/hep.0000000000000030","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T05:05:57Z","timestamp":1673499957000},"page":"1139-1149","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":35,"title":["Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis"],"prefix":"10.1097","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7802-0920","authenticated-orcid":false,"given":"Ismael","family":"El Hajra","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3795-3705","authenticated-orcid":false,"given":"Marco","family":"Sanduzzi-Zamparelli","sequence":"additional","affiliation":[{"name":"Liver Oncology Unit, Liver Unit, Hospital Cl\u00ednic, Barcelona, Spain"},{"name":"BCLC Group, IDIBAPS, Barcelona, Spain"},{"name":"CIBEREHD, Barcelona, Spain"},{"name":"Universitat de Barcelona (UB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4379-6486","authenticated-orcid":false,"given":"V\u00edctor","family":"Sapena","sequence":"additional","affiliation":[{"name":"Liver Oncology Unit, Liver Unit, Hospital Cl\u00ednic, Barcelona, Spain"},{"name":"BCLC Group, IDIBAPS, Barcelona, Spain"},{"name":"Universitat de Barcelona (UB), Barcelona, Spain"},{"name":"Medical Statistics Core Facility, Institut D\u2019Investigacions Biom\u00e9diques August Pi i Sunyer (IDIBAPS), Hospital Clinic Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-0575","authenticated-orcid":false,"given":"Sergio","family":"Mu\u00f1oz-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Liver Oncology Unit, Liver Unit, Hospital Cl\u00ednic, Barcelona, Spain"},{"name":"BCLC Group, IDIBAPS, Barcelona, Spain"},{"name":"CIBEREHD, Barcelona, Spain"},{"name":"Universitat de Barcelona (UB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-7676","authenticated-orcid":false,"given":"Ezequiel","family":"Mauro","sequence":"additional","affiliation":[{"name":"Liver Oncology Unit, Liver Unit, Hospital Cl\u00ednic, Barcelona, Spain"},{"name":"BCLC Group, IDIBAPS, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3209-0453","authenticated-orcid":false,"given":"Neus","family":"Llarch","sequence":"additional","affiliation":[{"name":"Liver Oncology Unit, Liver Unit, Hospital Cl\u00ednic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3908-8743","authenticated-orcid":false,"given":"Gemma","family":"Iserte","sequence":"additional","affiliation":[{"name":"Liver Oncology Unit, Liver Unit, Hospital Cl\u00ednic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-4950","authenticated-orcid":false,"given":"Alejandro","family":"Forner","sequence":"additional","affiliation":[{"name":"Liver Oncology Unit, Liver Unit, Hospital Cl\u00ednic, Barcelona, Spain"},{"name":"BCLC Group, IDIBAPS, Barcelona, Spain"},{"name":"CIBEREHD, Barcelona, Spain"},{"name":"Universitat de Barcelona (UB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0716-8784","authenticated-orcid":false,"given":"Jos\u00e9","family":"Rios","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Management Core Facility, IDIBAPS, Hospital Clinic Barcelona, Barcelona, Spain"},{"name":"Biostatistics Unit, Faculty of Medicine, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9826-0753","authenticated-orcid":false,"given":"Jordi","family":"Bruix","sequence":"additional","affiliation":[{"name":"Liver Oncology Unit, Liver Unit, Hospital Cl\u00ednic, Barcelona, Spain"},{"name":"BCLC Group, IDIBAPS, Barcelona, Spain"},{"name":"CIBEREHD, Barcelona, Spain"},{"name":"Universitat de Barcelona (UB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-9534","authenticated-orcid":false,"given":"Mar\u00eda","family":"Reig","sequence":"additional","affiliation":[{"name":"Liver Oncology Unit, Liver Unit, Hospital Cl\u00ednic, Barcelona, Spain"},{"name":"BCLC Group, IDIBAPS, Barcelona, Spain"},{"name":"CIBEREHD, Barcelona, Spain"},{"name":"Universitat de Barcelona (UB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"R1-20250824","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250824","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"R3-20250824","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"R4-20250824","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"R5-20250824","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"R9-20250824","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"R11-20250824","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2022.40.4_suppl.383","article-title":"Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEYNOTE-394 study","volume":"40","author":"Qin","year":"2022","journal-title":"J Clin Oncol"},{"key":"R12-20250824","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"R13-20250824","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J Hepatol"},{"key":"R14-20250824","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R15-20250824","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"R16-20250824","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"R17-20250824","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"R18-20250824","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"R19-20250824","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"R20-20250824","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study","volume":"65","author":"Marrero","year":"2016","journal-title":"J Hepatol"},{"key":"R21-20250824","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3892\/mco.2015.536","article-title":"Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma","volume":"3","author":"Da Fonseca","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"R22-20250824","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.09.031","article-title":"Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis","volume":"105","author":"McNamara","year":"2018","journal-title":"Eur J Cancer"},{"key":"R23-20250824","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12071968","article-title":"Effectiveness and safety of nivolumab in Child-Pugh B patients with hepatocellular carcinoma: a real-world cohort study","volume":"12","author":"Choi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R24-20250824","doi-asserted-by":"crossref","first-page":"e001033","DOI":"10.1136\/jitc-2020-001033","article-title":"Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study","volume":"8","author":"Fessas","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R26-20250824","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2021.39.15_suppl.4102","article-title":"Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers. [Abstract 4102]","volume":"39(Suppl)","author":"Chapin","year":"2021","journal-title":"J Clin Oncol"},{"key":"R27-20250824","doi-asserted-by":"crossref","first-page":"e16184","DOI":"10.1200\/JCO.2021.39.15_suppl.e16184","article-title":"Nivolumab\/pembrolizumab in Child-Pugh grade B\/C patients with advanced HCC. [Abstract e16184]","volume":"39(Suppl)","author":"Wong","year":"2021","journal-title":"J Clin Oncol"},{"key":"R28-20250824","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1200\/JCO.2022.40.4_suppl.397","article-title":"Atezolizumab plus bevacizumab in Child-Pugh B advanced hepatocellular carcinoma patients. [Abstract 397]","volume":"40","author":"Kim","year":"2022","journal-title":"J Clin Oncol"},{"key":"R29-20250824","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00432-018-2780-8","article-title":"Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers","volume":"145","author":"Finkelmeier","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"R30-20250824","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/cncr.32206","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: safety and clinical outcomes in a retrospective case series","volume":"125","author":"Kambhampati","year":"2019","journal-title":"Cancer"},{"key":"R31-20250824","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/apt.15245","article-title":"Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort","volume":"49","author":"Scheiner","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R32-20250824","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1111\/ajco.13454","article-title":"Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: experience of a tertiary Asian Center","volume":"17","author":"Ng","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"R33-20250824","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12071862","article-title":"Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: adjunctive role of the ALBI grade","volume":"12","author":"Pinato","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R34-20250824","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2021.08.020","article-title":"Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice","volume":"157","author":"Pinato","year":"2021","journal-title":"Eur J Cancer"},{"key":"R35-20250824","doi-asserted-by":"crossref","first-page":"e001945","DOI":"10.1136\/jitc-2020-001945","article-title":"Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors","volume":"9","author":"Wong","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R36-20250824","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study","volume":"76","author":"D\u2019Alessio","year":"2022","journal-title":"Hepatology"},{"key":"R37-20250824","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"R38-20250824","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","volume":"32","author":"Uno","year":"2014","journal-title":"J Clin Oncol"},{"key":"R39-20250824","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1080\/01621459.1998.10473722","article-title":"Restricted mean life with covariates: modification and extension of a useful survival analysis method","volume":"93","author":"Zucker","year":"1998","journal-title":"J Am Stat Assoc"},{"key":"R40-20250824","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"R42-20250824","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R43-20250824","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R44-20250824","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1055\/s-0038-1676805","article-title":"Child-Pugh classification: time to abandon?","volume":"39","author":"Kok","year":"2019","journal-title":"Semin Liver Dis"},{"key":"R45-20250824","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach\u2014the ALBI Grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"R46-20250824","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"R47-20250824","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2021.12.023","article-title":"Corrigendum to \u201cTowards a new definition of decompensated cirrhosis\u201d [J Hepatol 76 (2022) 202-207]","volume":"76","author":"D\u2019Amico","year":"2022","journal-title":"J Hepatol"},{"key":"R48-20250824","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.dld.2022.01.122","article-title":"Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function","volume":"54","author":"Cabibbo","year":"2022","journal-title":"Dig Liver Dis"},{"key":"R49-20250824","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41575-019-0179-x","article-title":"Insights into the success and failure of systemic therapy for hepatocellular carcinoma","volume":"16","author":"Bruix","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R50-20250824","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1007\/s10620-021-07365-9","article-title":"Effectiveness of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma in patients with hepatic decompensation","volume":"67","author":"Park","year":"2022","journal-title":"Dig Dis Sci"},{"key":"R51-20250824","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2147\/CEG.S256691","article-title":"Safety and efficacy of lenvatinib treatment in Child-Pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice: a multicenter analysis","volume":"13","author":"Ogushi","year":"2020","journal-title":"Clin Exp Gastroenterol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HEP.0000000000000030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T22:09:13Z","timestamp":1756073353000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HEP.0000000000000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/hep.0000000000000030","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"2022-06-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}